Ketanest-S (Esketamine Hydrochloride)

Esketamine is the S‑enantiomer of ketamine and acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By blocking this glutamate‑mediated excitatory pathway, it produces dissociative anesthesia, analgesia, and a reduction in central sensitization, facilitating rapid loss of consciousness and pain control.

The dose of Ketanest‑S is determined by the prescribing clinician based on the patient’s age, weight, medical condition, and the intended procedure. Dosage regimens are individualized and administered by qualified healthcare professionals in a monitored setting.

Safety data for esketamine during pregnancy and lactation are limited. It is classified as a Category C or unknown; therefore, it should only be used when the potential benefit justifies the potential risk to the fetus or infant, and only under specialist supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with racemic ketamine, esketamine provides a higher affinity for the NMDA receptor, allowing lower doses for equivalent anesthetic effect and potentially fewer psychotomimetic side effects. Unlike propofol, it maintains cardiovascular stability but may cause hypertension and tachycardia, making it suitable for specific clinical scenarios.

Ketanest‑S should be stored at controlled room temperature, typically below 25 °C, in its original sealed container. Protect the product from excessive moisture, direct sunlight, and temperature fluctuations. Do not freeze; inspect the vial for particulate matter before use.

Ketanest‑S is supplied as a sterile solution for injection and can be given intravenously or intramuscularly. Administration is performed by a qualified practitioner, who selects the appropriate route, dose, and rate of injection based on the patient’s clinical status and procedural requirements.

The most serious adverse events include respiratory depression, severe hypertension or cardiovascular instability, emergence delirium, and rare cases of psychosis or allergic reactions. Continuous monitoring of airway, breathing, circulation, and mental status is essential throughout the procedure and recovery period.

Ketanest‑S is contraindicated in patients with known hypersensitivity to esketamine or ketamine, those with uncontrolled severe hypertension, and individuals with a history of severe psychiatric disorders such as schizophrenia. Caution is also advised in patients with significant hepatic impairment or elevated intracranial pressure.